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ABSTRACT
We report for the ®rst time an analysis of the
ATPase activity of human DNA topoisomerase
(topo) IIb. We show that topo IIb is a DNA-dependent
ATPase that appears to ®t Michaelis±Menten
kinetics. The ATPase activity is stimulated 44-fold
by DNA. The kcat for ATP hydrolysis by human DNA
topo IIb in the presence of DNA is 2.25 s±1. We have
characterised a topo IIb derivative which carries a
mutation in the ATPase domain (S165R). S165R
reduced the kcat for ATP hydrolysis by 7-fold, to
0.32 s±1, while not signi®cantly altering the apparent
Km. The speci®city constant for the interaction
between ATP and topo IIb (kcat/Kmapp) showed a 90%
reduction for bS165R. The DNA binding af®nity and
ATP-independent DNA cleavage activity of the
enzyme are unaffected by this mutation. However,
the strand passage activity is reduced by 80%, pre-
sumably due to reduced ATP hydrolysis. The mutant
enzyme is unable to complement ts yeast topo II
in vivo. We have used computer modelling to pre-
dict the arrangement of key residues at the ATPase
active site of topo IIb. Ser165 is predicted to lie very
close to the bound nucleotide, and the S165R muta-
tion could thus in¯uence both ATP binding and ADP
dissociation.
INTRODUCTION
Type II topoisomerases are essential enzymes which are
required for the segregation of intertwined daughter chromo-
somes following replication (1±4). Their ability to control
DNA topology is also important during transcription, replica-
tion and recombination (reviewed in 4). A number of
anticancer drugs and antibiotics target the cleaved DNA
intermediate of the topoisomerase (topo) II reaction cycle,
leading to the formation of double-strand DNA breaks which
can result in cell death (reviewed in 5,6).
The catalytic cycle of type II topoisomerases is ATP
dependent. The ATPase domain is located at the N-terminus of
the protein. DNA stimulates ATP hydrolysis by 4- to 20-fold,
depending on the source of the enzyme and the reaction
conditions (7±10).
Type II topoisomerases alter the topology of DNA by
transiently cleaving one DNA helix, termed the gate helix, and
transporting a second helix through the enzyme-bridged break
(4,11,12). Extensive studies using pre-steady-state kinetic
techniques on yeast DNA topo II have enabled Lindsley and
co-workers to deduce how ATP binding and hydrolysis is
coordinated with DNA cleavage and transport during the
reaction cycle of eukaryotic topo II (13±18). The dimeric
enzyme binds the gate segment and cleaves it, generating an
intermediate where each monomer of topo II is covalently
linked to one DNA strand via the active site tyrosine residue.
The transported helix is thought to bind between the two
N-terminal ATPase domains, and ATP binding causes these
two domains to dimerise. One of the two bound ATP
molecules is subsequently hydrolysed and then the transported
segment is passed through the break in the gate segment. The
ATPs are hydrolysed sequentially with the products of the ®rst
ATP hydrolysis reaction released prior to hydrolysis of the
second ATP molecule. The transported helix is thought to exit
via the C-terminal dimer interface, although it is not clear how
this event correlates with hydrolysis of the second ATP
molecule (13±18).
Human cells contain two isoforms of DNA topo II, a and b
(reviewed in 19). The ATPase activity of human topo IIa has
been reported (10). To date no data have been published on the
ATPase activity of human DNA topo IIb. In this paper we
report the characterisation of the ATPase activity of human
DNA topo IIb. We also describe a mutated protein with
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reduced ATPase activity which results in loss of complemen-
tation activity.
MATERIALS AND METHODS
Wild-type human topo IIb and the mutant protein bS165R
were overproduced from plasmids YEphTOP2b-KLM (20)
and YEphTOP2bS16SR (21), respectively, in strain JEL1
DtopI (a leu2 trp1 ura3-52 prb1-1122 pep4±3 Dhis3::PGAL
10±GAL4 Dtop1), kindly provided by R. Hanai (Department of
Chemistry, Rikkyo University, Tokyo), then puri®ed to >95%
as described previously (21). Protein concentrations are
expressed in terms of topo II dimers throughout this paper.
Assay for ATP hydrolysis activity
ATP hydrolysis was assayed by a coupled enzyme assay (9),
which links ATP hydrolysis to NADH oxidation. Topo II was
incubated with 1 mM ATP, supercoiled plasmid (pBR322- or
pBluescript-derived), 2 mM phosphoenolpyruvate (PEP),
0.1 mM NADH, 5 U lactate dehydrogenase and 2.5 U
pyruvate kinase in relaxation buffer at 30°C. The concentra-
tions of topo II, ATP and DNA were varied as detailed in the
®gure legends. The rate of NADH oxidation was measured by
the decrease in absorbance over 3 min at 340 nm, and is
directly proportional to the rate of ATP hydrolysis.
Absorbance was measured using a Shimadzu UV-1601
spectrophotometer. All components except topo II and ATP
were in excess, as the doubling of the concentration of any
component did not increase the rate of NADH oxidation (data
not shown). No NADH oxidation was observed in the absence
of ATP. Previous work with yeast topo II suggested that the
ATP hydrolysis was not truly Michaelian (9). However our
data appears to ®t the Michaelis±Menten equation and, where
appropriate, our data were ®tted to the Michaelis±Menten
equation using GraphPad Prism: rate = Vmax[S]/([S] + Kmapp),
where Vmax is the maximum rate, [S] is substrate concentration
and Kmapp is the apparent Michaelis constant. Errors in ®tting
the data to each equation are expressed as 95% con®dence
intervals. Yeast topo II does not co-purify with topo IIb, so
will not contribute to the ATPase activity assayed here.
Complementation analysis
The viability of Saccharomyces cerevisiae strain JN394t2-4
(22) transformed with plasmids expressing wild-type or
mutated topo IIb was tested at 25 and 35°C on rich
media containing glucose, raf®nose or galactose as described
previously (20).
Strand passage activity assays
Decatenation and relaxation assays were carried out in
relaxation buffer (50 mM Tris±HCl pH 7.5, 0.5 mM EDTA,
1 mM DTT, 50 mM KCl, 30 mg/ml BSA) with 1 mg
supercoiled plasmid DNA or 400 ng kinetoplast DNA, 1 mM
ATP and 10 mM MgCl2 as described previously (21). Agarose
gels were photographed with a Bio-Rad Geldoc 1000 imager
and analysed using Tina v.2.08e software.
DNA binding and cleavage analysis
Gel retardation analysis was carried out as described previ-
ously (23). The DNA probes used were either a 40 bp linear
substrate, or a four-way junction that includes sequences from
the linear probe (23). Binding reactions were carried out for
45 min on ice in 20 ml of gel retardation (GR) assay buffer
(50 mM Tris±HCl pH 7.5, 0.5 mM EDTA, 1 mM DTT, 50 mM
KCl, 1% Triton X-100, 5% glycerol) containing 1 mg/ml
BSA. Cleavage reactions contained 600 ng topo IIb-derived
protein and the 40 bp linear substrate which had been labelled
at one end. Reactions were carried out in GR buffer with
10 mM MgCl2 or CaCl2 in the presence or absence of 10 mg/ml
m-AMSA and/or 1 mM ATP, and processed as described
previously (21).
Protein structure analysis
Protein structures were manipulated and displayed using
QUANTA, release 4.1.1, version 95.0320 (Molecular
Simulations Inc.) on a Silicon Graphics workstation.
Residues 35±472 of wild-type topo IIb were modeled onto
residues 1±391 of gyrase B using the program Modeler (24).
RESULTS
Intrinsic and DNA-stimulated ATPase activity of human
DNA topo IIb
The ability of DNA topo IIb to carry out ATP hydrolysis was
assayed spectrophotometrically using a coupled enzyme assay
(9). In the presence of 1 mM ATP, the rate of ATP hydrolysis
by wild-type topo IIb increased linearly with protein concen-
tration, both in the presence and absence of DNA (data not
shown). In the absence of DNA, the rate of ATP hydrolysis
was 0.025 s±1 enzyme dimer±1, whereas the addition of excess
supercoiled plasmid DNA increased the rate by 44-fold to
1.1 s±1 dimer±1, thus DNA stimulates the ATPase activity of
DNA topo IIb. This 44-fold stimulation by DNA is higher than
the 10-fold stimulation seen with human topo IIa when
analysed in a similar way (10).
Effect of DNA concentration on ATPase rate
The effect on the wild-type topo IIb ATPase activity of adding
different concentrations of supercoiled plasmid is shown in
Figure 1B (circles). Over 1000 bp of DNA per enzyme dimer
were required for full stimulation of ATPase activity, after
which the rate plateaus. The DNA concentration required to
give half maximal stimulation of wild-type topo IIb ATPase
activity was 160 bp dimer±1 (16 mM). This DNA concentration
most likely re¯ects the af®nity of the enzyme for the plasmid
DNA, rather than a requirement for a particular length of
DNA. It is notable that unlike human topo IIa there is no peak
of activity between 100 and 400 bp. This could be a function
of different assay conditions or it could re¯ect a difference in
the intrinsic properties of the b isoform, possibly related to
their different biological roles.
Determination of kcat and Km values for the ATPase
reaction of DNA topo IIb
The ATPase activity was assayed as a function of increasing
ATP concentration and the data were ®tted to the
Michaelis±Menten equation, as illustrated by the best ®t
curve in Figure 1A (solid curve). Lindsley and co-workers
have demonstrated that ATP hydrolysis by yeast topoisomer-
ase II is not truly Michaelian, but follows a complex scheme of
sequential hydrolysis of the two ATP molecules (9,13±18). At
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concentrations of ATP >350 mM, however, the
Michaelis±Menten equation is a good approximation for the
steady-state reaction (9,13). The kcat for topo IIb at 30°C was
2.25 6 0.5 s±1. The apparent Michaelis constant (Kmapp), was
0.63 6 0.4 mM for wild-type DNA topo IIb, which is
comparable to the 0.56±0.78 mM reported for DNA topo IIa
(10). The kcat is similar to the maximum rate of 2.17 s±1
dimer±1 observed for topo IIa (10). DNA gyrase and calf
thymus topo II also have comparable turnover rates of 1 s±1
dimer±1 and 1.1 s±1 dimer±1, respectively. These are all lower
than the kcat of the yeast enzyme, with rates of >7 s±1 dimer±1
(7±10).
Production of DNA topo IIbS165R, with a mutation in
the ATPase domain
During production of human DNA topo IIb expression
constructs an XbaI cloning site was introduced, causing a
serine to arginine change at S165R (21). This enzyme was
unable to complement yeast strains bearing a temperature-
sensitive mutation at the non-permissive temperature, whether
grown on rich or minimal media, or in the presence or absence
of glucose, galactose or raf®nose. Figure 2 shows a qualitative
assay with strain JN394top2-4 bearing plasmids encoding
topo II from yeast, human topo IIa, human topo IIb or human
topo IIbS165R grown on rich medium containing glucose.
Quantitative assays using equivalent numbers of cells indicate
that topo IIb complements as well as topo IIa and yeast topo II
in this strain, whereas bS165R does not complement at all
(data not shown). These results indicate that bS165R had not
retained suf®cient activity to ful®l its roles in vivo, unlike
wild-type topo IIb (20). We wished to determine the reason for
this lack of complementation. Circular dichroism analysis
showed that the mutation did not induce any gross structural
changes in the topo IIb (data not shown).
Ser165 lies in the ATPase domain, which is conserved from
prokaryotes to eukaryotes. The N-terminal ATPase domain of
human DNA topoisomerase IIb (21) is 21% identical to the
ATPase domain of Escherichia coli DNA gyrase B (25).
Figure 3 shows an alignment of the region surrounding Ser165
(conserved residues in bold). Many of the key residues at the
active site of gyrase B are conserved in eukaryotic topo II,
including the catalytic residue Glu42 (26), residue Asn46 and
the glycine-rich loop (Gly114, Gly117 and Gly119) in
subdomain 1. This glycine-rich loop (GXXGXG) corresponds
closely to the phosphate-binding loop (P-loop or Walker A
box) present in many adenine and guanine nucleotide-binding
proteins (reviewed in 27). It plays an important role in
nucleotide binding, as shown by X-ray crystallography (28),
and site-directed mutagenesis (9). Several other residues are
also involved in nucleotide binding by gyrase B (29,30); these
residues are marked with an asterisk in Figure 3, for example,
Lys103, which forms a salt bridge with the b-phosphate of
bound AMPPNP (28). However, as shown in the alignment in
Figure 3, the nucleotide-binding residue Lys103 is not
conserved between prokaryotic and eukaryotic enzymes, and
neither are the residues immediately preceding it. Multiple
sequence alignments indicate that in eukaryotic DNA topo II
the amino acid residue that corresponds to Lys103 in gyrase B
is an asparagine residue, Asn166 in human DNA topo IIb.
Many of the residues preceding Asn166 are conserved
between eukaryotic type II topoisomerases, but not with the
Figure 1. (A) Dependence of the topo IIb and bS165R ATPase rates on
ATP concentration. The rate of ATP hydrolysis is plotted against ATP con-
centration for 100 nM wt topo IIb (circles) or bS165R (open triangles).
DNA was present at 600 bp dimer±1 (60 mM). The curve drawn through the
points is calculated from the Michaelis±Menten equation. Wild-type (wt)
topo IIb: kcat = 2.25 6 0.5 s±1 dimer±1, Km = 0.63 6 0.4 mM. S165R: kcat =
0.32 6 0.14 s±1 dimer±1, Km = 1.0 6 0.9 mM. (B) Dependence of topo IIb
and bS165R ATPase rates on DNA concentration. The rate of ATP hydro-
lysis is plotted against DNA concentration for 100 nM wt topo IIb (circles)
or bS165R (open triangles). ATP was present at 1 mM. A hyperbolic curve
is ®tted to each data set. wt topo IIb: Vmax = 1.74 6 0.2 s±1 dimer±1, Kd =
160 6 65 bp dimer±1 (16 mM). For bS165R, Vmax = 0.18 6 0.08 s±1
dimer±1, Kd = 163 bp dimer±1.
Figure 2. bS165R does not complement temperature-sensitive yeast topo II.
In vivo complementation of yeast strain JN394top2-4. Yeast transformants
expressing plasmid-borne type II topoisomerases were streaked onto YPDA
plates and incubated at 25 or 35°C as indicated. A number of proteins were
tested (plasmid names in parentheses); vector control (YCP50), yeast topo II
(GIT2), human topo IIa (YEpWOB6), human topo IIbS165R
(YEphTOP2bS165R) or human topo IIb wt (YEphTOP2bKLM). Human
topo IIbS165R was unable to complement JN394top2-4 at 35°C.
5418 Nucleic Acids Research, 2002, Vol. 30, No. 24
prokaryotic enzymes. Two conserved residues from sub-
domain 2 are also within hydrogen bonding distance of the
bound ATP: Gln335 and Lys337. Site-directed mutagenesis
has revealed that only Lys337 is critical for ATPase activity
(31,32). In the present study we have investigated whether the
inability of bS165R to complement yeast topo II is due to a
de®ciency in its ATPase activity.
ATPase activity of human DNA topo IIb S165R
In the presence of 1 mM ATP the rate of DNA-stimulated ATP
hydrolysis by bS165R was found to be directly dependent on
the protein concentration (data not shown). The rate of ATP
hydrolysis was 0.072 s±1 dimer±1, 15-fold lower than the 1.1 s±1
of the wild-type enzyme. ATP hydrolysis by bS165R in the
absence of DNA was too low to measure reproducibly.
Effect of DNA concentration on ATPase rate
ATP hydrolysis was assayed over a range of DNA concen-
trations to determine whether the bS165R mutant had an
altered response to DNA. These results are shown in Figure 1B
(open triangles). Over 1000 bp of DNA per enzyme dimer
were required for full stimulation of ATPase activity of
bS165R, the same as seen for wild-type topo IIb. The DNA
concentration to achieve half maximal stimulation was not
signi®cantly different for wild-type topo IIb (160 bp dimer±1)
and bS165R (163 bp dimer±1). This suggests that the reduced
ATPase activity of bS165R does not arise from a lower
af®nity for DNA than the wild-type enzyme.
The S165R mutation reduces the kcat for ATP hydrolysis
but does not signi®cantly affect the Kmapp
To test if the reduced rate of ATP hydrolysis by bS165R arose
from an altered af®nity for ATP, DNA-stimulated ATP
hydrolysis was assayed over a range of ATP concentrations.
The data can be ®tted to the Michaelis±Menten equation, as
illustrated by the best ®t curve in Figure 1A (open triangles).
The kcat for bS165R was 0.32 6 0.14 s±1, 7-fold lower than the
kcat for wild-type topo IIb (2.25 6 0.5 s±1). These data indicate
that the S165R mutation has reduced the rate of ATP
hydrolysis to 14% of that of the wild-type topo IIb. The two
proteins had similar values for the apparent Michaelis constant
(Kmapp), at 0.63 6 0.4 and 1.0 6 0.9 mM for wild-type topo
IIb and bS165R, respectively. The speci®city constant for the
interaction between ATP and topo IIb (kcat/Kmapp) is thought
to be dependent solely on rate constants involved in ATP
binding and has no dependence on the rate constants for ATP
hydrolysis and product release (13). kcat/Kmapp was 3.57 3 103
M±1 s±1 for wild-type topo IIb and 0.32 3 103 M±1 s±1 for
bS165R, a reduction of 90%. This suggests that some aspect of
ATP binding has been altered in the bS165R protein.
The S165R mutation does not affect DNA binding or
ATP-independent cleavage
The data in Figure 1B suggested that the af®nity for DNA was
not altered by the S165R mutation. To con®rm this, gel
retardation assays (23) were used to investigate whether the
S165R mutation had altered the binding of topo IIb to DNA.
Titration curves showed that bS165R was as effective as wild-
type topo IIb in binding to both a linear 40 bp duplex
containing a single topo II cleavage site (Fig. 4A and C) and to
a synthetic four-way junction of related sequence (Fig. 4B and
C) (23). Furthermore, the complexes of wild-type topo IIb and
bS165R with DNA showed very similar stabilities in response
to increasing salt concentration (data not shown). These
results indicate that the ability of topo IIb to bind either linear
or four-way junction DNA was not altered by the S165R
mutation.
The linear substrate used in the gel retardation assay
contains a single topo IIb cleavage site and cleavage at this site
is stimulated by the topo II poison m-AMSA. Cleavage by
wild-type topo II and bS165R was assayed in the absence of
ATP, and in the presence of Mg2+ (Fig. 5A, lanes 2 and 6),
Mg2+ with m-AMSA (Fig. 5A, lanes 3 and 7), Ca2+ (Fig. 5A,
lanes 4 and 8) or Ca2+ with m-AMSA (Fig. 5A, lanes 5 and 9;
see also Fig. 5B). Magnesium ions support both DNA
cleavage and ATP hydrolysis by topo II, whereas calcium
ions can only support DNA cleavage. Under all four condi-
tions bS165R (Fig. 5A, lanes 6±9) had similar DNA cleavage
activity to wild-type topo IIb (Fig. 5A, lanes 2±5). The ability
of bS165R to carry out ATP-independent site-speci®c cleav-
age both in the presence and absence of m-AMSA was
therefore unchanged with respect to the wild-type enzyme.
The addition of ATP increased Mg2+-dependent cleavage by
wild-type topo IIb by 2-fold, both with and without m-AMSA.
However, cleavage by bS165R was not affected by ATP
(Fig. 5B).
Figure 3. Alignment of the amino acid sequences surrounding Ser165 of topo IIb. Conserved residues are indicated in bold. Asterisks indicate residues in
E.coli gyr B which make hydrogen bonds to AMPPNP: Lys103, Tyr109, Leu115, His116, Val118 and Gly119. The box includes residues of the highly con-
served glycine loop, Gly114, Gly117 and Gly119.
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The strand passage activity of the bS165R mutant is
reduced by >80%
The strand passage activities of wild-type topo IIb and
bS165R were assayed in order to determine whether the 7-fold
reduction in the ATP hydrolysis activity of bS165R had
affected the overall rate of catalysis. Figure 6 shows relaxation
assays performed with increasing concentrations of wild-type
topo IIb (Fig. 6A) or bS165R (Fig. 6B). Wild-type topoIIb is
more processive than bS165R in relaxation assays. The
protein concentration required to relax 50% of the supercoiled
plasmid DNA was calculated to be 1.9 nM for wild-type topo
IIb and 11.7 nM for bS165R, and thus the mutant protein has
16% of the wild-type relaxation activity. Both wild-type topo
IIb and bS165R had the same or greater activity at 37
compared with 25°C, indicating that the activity of bS165R is
not temperature sensitive (Fig. 6C).
Decatenation assays with increasing concentrations of
protein also showed that bS165R had only 20% of wild-type
strand passage activity (Fig. 7A and B). Fifty per cent of the
kDNA was decatenated by 0.97 nM topo IIb whereas 4.7 nM
bS165R was required for the same level of activity. The
dependence of decatenation on Mg2+ concentration was also
examined, and both wild-type topo IIb and bS165R had near
maximal activity between 5 and 30 mM Mg2+ (33; data not
shown).
Relaxation assays were also carried out in the presence of
the topo II inhibitor ICRF-193, which stabilises the closed
clamp form of the enzyme (34). Increasing concentrations of
ICRF-193 were added to relaxation assays containing wild-
type topo IIb (Fig. 8A) or bS165R (Fig. 8B). bS165R was less
sensitive to inhibition by ICRF-193. The concentration of
ICRF-193 required for 50% inhibition of activity (IC50) was
1.9 mM for wild-type topo IIb and 3.5 mM for bS165R.
Modelling of the ATPase domains of wild-type topo IIb
and bS165R
The ATPase domain of DNA topo IIb is only 21% identical to
that of E.coli DNA gyrase B, and although the X-ray crystal
structure of the gyrase B ATPase domain has been determined,
there is no structural information for this domain of the
eukaryotic type II enzymes. To investigate whether the
ATPase domains of eukaryotic and prokaryotic type II
topoisomerases could be structurally similar, the ATPase
domain of wild-type topo IIb was modelled onto the ATPase
domain of DNA gyrase B (28). Superimposition of the
modelled topo IIb onto gyrase B (Fig. 9A) reveals that the
structures are very similar, although small differences in the
shapes of many of the intervening loops can be observed.
The arrangement of key residues around the active site of
gyrase B is maintained in the modelled structure of wild-type
topo IIb, as shown in Figure 9B and C. The nucleotide-binding
residues Asn46 (Asn107 in topo IIb), Asp73 (Asn136 in topo
IIb) and the glycine loop are conserved between gyrase B and
topo IIb, and the positions of these residues within the active
sites are almost identical. Gln335 (Gln392) and Lys337
(Lys394) from subdomain 2 also have very similar positions in
gyrase B and topo IIb. This is consistent with previous
observations that the residues equivalent to Gly117 of the
glycine-rich loop and Gln335 and Lys337 of subdomain 2 play
very similar roles in both topo II and DNA gyrase (9,32).
The nucleotide-binding residues Lys103 and Tyr109 cor-
respond to Asn166 and Lys172 in topo IIb, and the locations
of these residues are very similar, although the exact positions
of the different side chains are a little different. The catalytic
residue Glu42 (Glu103 in topo IIb) has the same position in
gyrase B and topo IIb. The residue corresponding to His38,
which is important for aligning and polarising Glu42, is Lys99
in topo IIb. However, the side chain of Lys99 is not directed
Figure 4. Wild-type topo IIb and bS165R have similar DNA binding af®n-
ities. A gel retardation assay was employed to study DNA binding.
(A) Linear DNA probe was incubated with 0, 6.9, 13.9, 20.8, 27.8, 41.7, 55.6,
69.4, 83.3 and 97.2 nM bS165R in lanes 1±10, respectively. (B) Four-way
junction substrate was incubated with 0, 1.4, 3.5, 4.9, 6.9, 10.4, 13.9, 20.8,
27.8 and 34.7 nM bS165R in lanes 1±10, respectively. (C) Quanti®cation of
DNA binding. Filled circles, wt topo IIb on linear DNA; open triangles,
bS165R on linear DNA; open circles, wt topo IIb on four-way junction
DNA; ®lled triangles, bS165R on four-way junction DNA. The
protein±DNA complexes were quanti®ed and are plotted as a percentage of
the input DNA against protein concentration.
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towards Glu103 in the topo IIb model, and is thus not suitable
for aligning the active glutamate residue. Lys99 lies just after
a loop of 21 residues which has no counterpart in
gyrase B. Modelling the shape and orientation of this loop is
less accurate than modelling regions where topo IIb and
gyrase B align well, and it is possible that assigning an
incorrect structure to the loop could result in a misalignment
of the residues adjacent to it, including Lys99. Lys99 is
conserved in all eukaryotic type II topoisomerases, and there
do not appear to be any other nearby residues which could
perform this function instead.
The modelling was repeated using the bS165R sequence to
investigate whether the mutation could have introduced
signi®cant structural alterations within the ATPase domain.
The resulting structure was virtually identical to that of wild-
type topo IIb. This suggests that the reduction in ATPase
activity observed for this mutant is unlikely to arise from gross
structural changes. The residues at the active site of bS165R
are predicted to have identical positioning to those in topo IIb
(compare Fig. 9C and B). The substituted arginine residue
does not affect the positioning of any other residues and does
not appear to protrude into the predicted AMPPNP binding
site, although it would be in close proximity to the bound
nucleotide.
DISCUSSION
This paper reports for the ®rst time the kinetics of ATP
hydrolysis by human topo IIb. The kcat for topo IIb at 30°C
was 2.25 s±1, which is comparable to the 2.17 s±1 dimer±1
previously reported for human topo IIa at optimal DNA
concentrations at 37°C (10). DNA gyrase and calf thymus
topo II have comparable rates of 1 s±1 and 1.1 s±1, respectively
(7,8), and yeast and Drosophila topo II have the highest rates
of ATP hydrolysis, at 7 s±1 and 5±13 s±1 (9,35±37).
The rate of ATP hydrolysis was stimulated 44-fold by
supercoiled plasmid DNA, which is greater than the 10-fold
stimulation seen for topo IIa. Type II topoisomerases from
other species also show DNA stimulation of between 4- and
20-fold. For example, yeast topo II and DNA gyrase both show
20-fold stimulation of ATP hydrolysis by DNA, whilst calf
thymus topo II shows only a 4-fold stimulation by DNA.
However, the calf thymus enzyme studied was not full length,
but a mixture of 140 and 125 kDa proteolytic fragments which
may not have exactly the same characteristics as the full-
length enzyme (7±10).
It is notable that as the DNA concentration is increased,
topo IIb ATPase activity does not spike at 100±400 bp
dimer±1, unlike topo IIa (10,38). This hyperstimulation
Figure 5. DNA cleavage by wt topo IIb and bS165R. (A) Cleavage reactions contained linear DNA probe and 56 nM each protein: lanes 2±5, wt topo IIb;
lanes 6±9, bS165R. Cleavage was assayed in the presence of: 10 mM Mg2+ (lanes 1, 2 and 6), 10 mM Mg2+ and m-AMSA (lanes 3 and 7), 10 mM Ca2+
(lanes 4 and 8) or 10 mM Ca2+ and m-AMSA (lanes 5 and 9). The uncleaved 40 bp substrate is indicated by S, and the 21 bp labelled cleavage product is
indicated by P. Labelling of both DNA strands revealed that wt topo IIb and bS165R cleaved the two strands equally (data not shown). (B) Histograms
comparing cleavage by wt topo IIb (grey) and bS165R (black) in the presence of 10 mM Mg2+ with and without ATP (left), 10 mM Mg2+ and m-AMSA with
and without ATP (middle) and 10 mM Ca2+ or 10 mM Ca2+ and m-AMSA (right). Results are expressed relative to background and are derived from a
different experiment to that shown in (A).
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phenomenon has been interpreted by Campbell and Maxwell
(38) as arising from protein±protein interactions between topo
II dimers that are bound adjacent to each other on one piece of
DNA. The difference in the DNA hyperstimulation between
human DNA topo IIa and DNA topo IIb could result from a
difference in their abilities to interact with adjacent dimers
that re¯ect isoform-speci®c cellular functions. For example,
topo IIa has been shown to associate with sites of DNA
replication, whereas topo IIb does not (39,40). Alternatively,
the presence of a spike in ATPase activity at particular DNA
concentrations may have some dependence on reaction
conditions. For example, with topo IIa Hammonds and
Maxwell (10) report that the rate of ATPase activity in the
spike is very sensitive to the monovalent cation concentration.
Furthermore, they report unpublished data of similar hyper-
stimulation for yeast topo II, yet Lindsley's group have never
reported this phenomenon in their extensive studies on the
same enzyme. The cation concentration used in this study was
50 mM, while those used by Maxwell's group were 125 (10)
and 10 mM (38). Olland and Wang (41) demonstrated a spike
in ATPase activity for an N-terminal fragment of yeast topo II
at 50 mM KCl but not at 100 mM KCl. They postulate that the
monomer±dimer equilibrium of this fragment may have
in¯uenced these results. Olland and Wang also suggest that
the hyperstimulation previously observed for full-length topo
IIa may arise from a lower rate of ATPase activity on certain
weak DNA-binding sites. In conclusion, it is not clear whether
the absence of DNA hyperstimulation for topo IIb re¯ects a
true difference from the a isoform or simply a difference in
reaction conditions, and this determination will await testing
of the two isoforms under identical laboratory conditions.
DNA binding and DNA cleavage in the absence of ATP
appear to be unaffected by the S165R mutation. ATP
stimulates DNA cleavage by wild-type topo IIb by ~2-fold;
however, no ATP stimulation of cleavage was seen with
bS165R. Previous studies have shown that etoposide, another
topoisomerase II poison, inhibits DNA religation after
hydrolysis of the ®rst ATP molecule and the release of its
products (18,42). Hydrolysis of the second ATP molecule is
inhibited by etoposide. Our data are consistent with this
scheme, with the reduced rate of ATP binding and hydrolysis
in S165R resulting in an absence of ATP-stimulated cleavage.
The reduction in ATPase activity is re¯ected in a 5-fold
reduction in strand passage activity in both relaxation and
decatenation assays. Consequently, bS165R is unable to
complement the functions of ts yeast topo II at the non-
Figure 7. bS165R has reduced decatenation ability compared to wt topo
IIb. Topo II was incubated with 400 ng kinetoplast DNA (kDNA) in the
presence of ATP at 37°C for 30 min. (A) Minicircles released by topo II
activity are indicated (m/c). Lanes 1±7: 0, 0.7, 1.4, 2.8, 5.6, 8.3 and 11.1 nM
wt topo IIb; lanes 8±16: 0, 1.4, 2.8, 5.6, 8.3, 11.1, 13.9, 16.7 and 19.4 nM
bS165R. These data are plotted as percentage decatenation against concen-
tration of wt topo IIb (®lled circles) and bS165R (open triangles) in (B).
Figure 6. bS165R has reduced relaxation activity compared to wt topo IIb.
Increasing concentrations of wt topo IIb (A) or bS165R (B) were incubated
with 1 mg supercoiled plasmid DNA (s/c) in the presence of ATP for 30 min
at 37°C. Relaxed plasmid is indicated (rel). (A) Lanes 1±8 contained 0,
0.69, 1.4, 2.8, 4.2, 5.6, 6.9 and 10.4 nM protein, respectively. (B) Lanes 1±9
contained 0, 3.5, 6.9, 10.4, 13.9, 17.4, 20.8, 27.8 and 34.7 nM protein,
respectively. (C) The relaxation activity of wt topo IIb (triangles) and
bS165R (circles) was assayed at both 25 (®lled symbols) and 37°C (open
symbols). The percentage of supercoiled DNA remaining is plotted against
protein concentration.
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permissive temperature in vivo. These results show that
ef®cient ATP hydrolysis is crucial to topo II function in vivo.
The relaxation assays also indicate that bS165R is more
processive than wild-type topo IIb. As the S165R mutation
does not affect DNA binding, the more distributive relaxation
pattern of bS165R is probably due to its reduced strand
passage activity, allowing more time to dissociate and
reassociate with the substrate DNA between reaction cycles.
In the kinetic scheme proposed by Lindsley and co-workers
for ATP hydrolysis by topo II, kcat/Kmapp includes only terms
involved in ATP binding. While we ®nd that Kmapp is
unchanged by the S165R mutation, kcat/Kmapp is reduced by
10-fold, suggesting that some aspect of ATP binding has been
altered. To investigate how the mutation might affect the ATP
binding pocket, we used computer modelling to predict the
structure of the topo IIb ATPase domain, based on the DNA
gyrase B structure (28). The arrangement of key residues at the
active site is predicted to be very similar to that in DNA gyrase
B. The residue adjacent to Ser165, Asn166, aligns with the
gyrase B residue Lys103, which forms a salt bridge with the b-
phosphate of the bound ATP (28). In topo IIb, Asn166 appears
to be in a suitable position to form a hydrogen bond with ATP.
The adjacent Ser165 may also interact with the bound ATP, or
it could help to position Asn166 correctly. Replacement of
serine with arginine could thus remove contacts that are
important for ATP binding. The positively charged side chain
of the introduced arginine residue could also in¯uence the
binding and positioning of ATP within the binding pocket, as
it is predicted to lie close to the ribose and adenine rings.
The S165R mutation caused a 7-fold reduction in kcat,
which re¯ects the rate of ATP hydrolysis and product release.
In the presence of saturating ATP concentrations, release of
the ADP and Pi products is rate determining. The proximity of
the Arg165 side chain to the ribose and adenine rings of the
ATP leads us to speculate that the reduction in kcat may be due
to a reduction in the dissociation rate of ADP, rather than a
reduction in the rate of substrate to product conversion.
However, more detailed kinetic analyses are necessary to test
this hypothesis.
In summary, the S165R mutation is the ®rst reported
mutation in the ATPase domain of human DNA topo IIb. Our
data show that this mutation affects the ATPase activity of the
enzyme, reducing the kcat for ATP hydrolysis by 7-fold, and
reducing the kcat/Kmapp by 10-fold. DNA binding and DNA
cleavage in the absence of ATP appear to be unaffected.
The reduction in ATPase activity is re¯ected in a 5-fold
reduction in relaxation activity. Consequently, bS165R is
unable to complement the functions of ts yeast topo II at the
non-permissive temperature in vivo. These results show that
ef®cient ATP hydrolysis is crucial to topo II function in vivo
and also indicate that ATP hydrolysis is not required for DNA
binding or cleavage.
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Figure 9. Modelling of the ATPase domain of DNA topo IIb onto the
X-ray crystal structure of E.coli DNA gyrase B ATPase domain. (A)
Superimposition of the modelled ATPase domain of topo IIbS165R (blue)
(amino acids 35±472) onto that of gyrase B (red) (amino acids 1-391).
(B±D) Arrangement of the key residues round the active sites of (B)
gyrase B, (C) the modelled structure of wt topo IIb and (D) the modelled
structure of bS165R. The bound AMPPNP is shown in red in (B).
Figure 8. Inhibition of relaxation activity by ICRF-193. Relaxation
reactions were performed with (A) wt topo IIb in the presence of 0, 1, 2, 3,
4, 5 or 6 mM ICRF-193 as indicated or (B) bS165R in the presence of 0, 1,
2, 3, 4, 5, 6 or 7 mM ICRF-193 as indicated.
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